
Cancer medicine unlocks the softer death for TB Culprit
A medication for cancer treatment currently in clinical trials could strengthen tuberculosis therapy by triggering a more controlled cell death process, which potentially reduces pulmonary damage in survivors, according to medicine researchers Johns Hopkins. The Navitoclax experimental medicine, when added to standard tuberculosis (TB) treatments, helped infected cells through a controlled process called apoptosis instead…